



wherein the 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is [a saturated hydrocarbon radical having 6 to 9 carbon atoms or] a radical of formula II:



where:

- X is S or O;
- Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;
- Z is a single bond, or
a bivalent radical comprising
 - (1) O, or
 - (2) S, or
 - (3) $-CR^2-$, where R is H or (C_1-C_4) -alkyl, or

(4) [a bivalent radical having] from 2 to 10 carbon atoms linked in the form of a chain, which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, or

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing bivalent radicals, the free valences of the carbon atoms of said bivalent radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof; and

Ar is an aromatic ring system having one or two rings which can be substituted by one, two, or three radicals, which may be identical or different, which are halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, or trifluoromethoxy; [and] the pharmaceutical composition further comprises at least one anionic, cationic, nonionic, or amphoteric surfactant, or a mixture thereof; and
the pharmaceutical composition has a pH in the skin-physiologically tolerable range.


32. The pharmaceutical composition as claimed in claim 27 in which the 1-hydroxy-2-pyridone of formula I comprises Ar as a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

33. The pharmaceutical composition as claimed in claim 27 in which the 1-hydroxy-2-pyridone of formula I is 1-hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxy-methyl]-2(1H)pyridone, or a pharmaceutically acceptable salt of thereof.

34. A pharmaceutical composition for treatment of a human or animal patient in need of treatment for seborrheic dermatitis comprising an efficacious amount of a 1-hydroxy-2-pyridone of formula I, wherein the 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



(I)

where R¹, R², and R³, which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R⁴ is a saturated hydrocarbon radical having 6 to 9 carbon atoms;

the pharmaceutical composition further comprises at least one anionic, cationic, nonionic, or amphoteric surfactant, or a mixture thereof; and
the pharmaceutical composition has a pH from about 4.5 to about 6.5.

35. The pharmaceutical composition as claimed in claim 34 in which the 1-hydroxy-2-pyridone of formula I comprises a cyclohexyl radical in the R⁴ position.

36. The pharmaceutical composition as claimed in claim 34 in which the 1-hydroxy-2-pyridone of formula I comprises an octyl radical of the formula -CH₂-CH(CH₃)-CH₂-C(CH₃)₃ in the R⁴ position.

37. The pharmaceutical composition as claimed in claim 34 in which the 1-hydroxy-2-pyridone of formula I is 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the foregoing. --

REMARKS

Without acquiescing in the rejections, and without prejudice to pursue broader claims in a continuation application, Applicants have canceled claims 14-26 and 31. In claim 27, the preamble was changed, and the definition of the radical R⁴ was limited to that of a radical of formula II. Clause (4) of the definition of Z was also amended to